• XESP is a market disruptor offering cutting-edge data analysis and intelligent technology to help companies reach their target markets
• The company’s Digital Engagement Engine(TM) technology platform provides clients with meaningful connections that guide their audiences from awareness to action
• Electronic Servitor Publication Network’s disruptive solution helps clients maintain complete control of their content while dynamically connecting with current and new audiences to drive growth

Electronic Servitor Publication Network (OTCQB: XESP) is a market disruptor focused on connecting companies with target audiences to drive predictable growth. XESP’s managed service provides B2B clients with cutting-edge data analysis and intelligent technology to help them reach and connect with their target markets and audiences. XESP helps companies – and their products and services – connect by digitally engaging audiences with content and dialog that otherwise and ordinarily could only be done through direct contact by sales personnel. Their service provides around-the-clock company-consumer interactions, instead of just momentary and episodic contact, to drive growth.

The company has developed the Digital Engagement Engine(TM), a technology platform specifically designed for digital activation and engagement. It is built on workflows and microservices that automate tasks to help companies connect with people digitally, while reducing costs, enhancing user engagement, and achieving growth targets.

There are several excellent customer relationship management (“CRM”), optimization, and omnichannel content publication tools available to companies.  However, the modern companies with whom XESP has interacted, have found that existing tools and technologies have not provided desired results or growth. The cause is multi-faceted, including a lack of integration and costly management of the tools, but the solution these challenges is embedded in the design the Digital Engagement Engine(TM).

XESP has identified deficiencies in how companies represent themselves through digital channels.  Most companies stick to monologues that present their messages and stories without input from the target audience, whereas the modern approach is a two-way dialogue or “conversation” between the company and its customers.

Through its technology stack, XESP solves these challenges by having all tools working together and then leveraging the Digital Engagement Engine(TM), which uniquely handles content provisioning, to promote meaningful interactions between the clients and their audiences.

“The Digital Engagement Engine(TM) overlays with the tools to ensure that you are having a co-created conversation that is meaningful to the individual user rather than a one-size-fits-all. And that meaningful interaction drives a greater relationship with your audience, greater trust, and, ultimately, greater growth in your organization. Very simply put, it replicates what you do face to face, and if we can do that online, which the digital engagement helps you do, you’re going to produce better results,” explained XESP CEO Peter Hager in a recent interview with Spotlight TV (https://ibn.fm/AcoQq).

“So, there’s no need to go out and not leverage a tool that you already have or purchase a new tool. It’s about getting the people and the tools aligned with the right processes to drive the experience and results that CEOs are demanding,” Hager continued.

XESP’s intelligent tech stack, which utilizes data management, also embraces various public social platforms as vital sources of market intelligence and avenues through which companies interact with their customers “on their terms.” By supporting the various social media platforms, XESP lets end consumers decide how they want to interact with brands and their content and the technology stack makes these interactions more meaningful.

All things considered, the company’s disruptive solution helps clients maintain complete control of their content while dynamically connecting with current and new audiences to drive growth.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Skylar recently announced a collaboration with Amazon Prime Video as the official fragrance of “The Summer I Turned Pretty” series
• To celebrate the partnership, Skylar released three rollerball fragrances featuring “The Summer I Turned Pretty” branding: Salt Air, Boardwalk Delight, and Capri Summer
• Skylar fragrances are cruelty-free, vegan, hypoallergenic, and formulated without any of the 36 known perfume allergens or 1,300+ “questionable” ingredients
• Starco Brands, Inc. is an invention factory that invents or acquires innovative products with behavior-changing technologies and leverages an extensive network of manufacturing, distribution, and media partners
• Other Starco Brands include the Art of Sport premium skincare line co-founded by Kobe Bryant, Whipshots(R) vodka-infused whipped cream featuring Cardi B, Winona Pure(R) theater-style popcorn spray and the Soylent line of nutrient-dense food products

The Skylar division of Starco Brands (OTCQB: STCB) makes clean, hypoallergenic fragrances designed to empower individuals with scents that make them feel safe, beautiful, and confident in their skin. The company recently announced its partnership with Amazon Prime Video as the official fragrance of “The Summer I Turned Pretty” – a coming-of-age series that explores themes of love, relationships, identity, and self-discovery.

In celebration of Skylar’s partnership with Amazon Prime Video, the company released three rollerball fragrances featuring “The Summer I Turned Pretty” branding: Salt Air, Boardwalk Delight, and Capri Summer. Vegan, eco-friendly, and hypoallergenic, each limited-edition rollerball is designed to invoke youthful emotions and memories inspired by the sweet scents of summer.

Skylar was founded in 2017 to address allergic reactions to everyday fragrances. Fragrance allergies are relatively common, affecting over two million Americans with symptoms that include eyelid tearing, skin redness, swelling, burning sensations, headaches, breathing difficulties, sneezing, and nasal congestion.

Formulated without any of the 36 known allergens or 1,300+ “questionable” mainstream perfume ingredients, Skylar’s scents are inspired by the spirit and natural landscapes of California. The entire product line, including full-sized fragrance bottles, rollerballs, candles, and gift sets, is available at the company’s online store, 500+ Sephora locations, and through the Skylar Scent Club, which sends products to 10,000+ subscribers each month.

Since its acquisition by Starco Brands, Inc. in Jan. 2023, Skylar continues to operate as a separate business unit. Other products under the Starco Brands umbrella include Winona Pure(R) theater-style popcorn spray powered by air, the award-winning Soylent line of nutrient-dense food products, the Art of Sport premium skincare line co-founded by Kobe Bryant and Whipshots(R) vodka-infused whipped cream featuring Cardi B.

Starco Brands aims to spark delight in the everyday by inventing or acquiring products with behavior-changing technologies. The company’s revenues skyrocketed in 2022 from $2 million to approximately $67 million through a strategy that identifies gaps in eight core consumer categories and fulfills that demand with novel products that disrupt markets, change behaviors, and exceed consumer expectations.

Based in Santa Monica, California, Starco Brands is led by a management team with decades of experience in consumer goods, M&A, business development, and finance. With a stellar product strategy backed by a solid network of manufacturing, distribution, and media partners, the company is strongly positioned to capture a significant share of every market it enters with its portfolio of innovative, behavior-changing brands.

For more information, visit the company’s website at www.StarcoBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB

• Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer
• This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3
• Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq
• The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023
• Genprex is combining its lead product candidate, REQORSA, with existing lung cancer medications – Tagrisso, Keytruda, and Tecentriq – in an effort to help patients benefit for longer periods of time and allow some patients to benefit who may not have benefited at all

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. Food and Drug Administration (“FDA”) Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment (https://ibn.fm/jIv3I).

The FTD is for the company’s Acclaim-3 patient population, and Genprex expects to initiate its Acclaim-3 clinical trial by enrolling the first patient in the third quarter of 2023. The Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq. Patients in this study will be enrolled after receiving treatment with 3-4 cycles of carboplatin, etoposide, and Tecentriq and achieving a complete response, partial response, or stable disease. They will then receive treatment with REQORSA and Tecentriq as maintenance therapy every 21 days until disease progression.

The company has previously received two other FTDs. In 2020, Genprex announced that the FDA had granted FTD for its REQORSA therapy in combination with AstraZeneca’s (NASDAQ: AZN) Tagrisso(R) in patients with late-stage non-small cell lung cancer (“NSCLC”) whose disease has progressed after treatment with Tagrisso (https://ibn.fm/p5bPW). Later, in 2022, the company received its second FTD for REQORSA in combination with Merck & Co Inc.’s (NYSE: MRK) Keytruda(R) in patients whose disease progressed after treatment with Keytruda(R) (https://ibn.fm/Asm5m).

To get a Fast Track Designation, a drug company must file an application with the FDA and provide all non-clinical and clinical data demonstrating the potential for a drug to benefit patients with a serious or life-threatening disease where there is an unmet need. “Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one,” explains the FDA (https://ibn.fm/nFpR4).

“This is another exciting achievement in our REQORSA drug development program, which further validates REQORSA’s potential not only in NSCLC but also in SCLC. We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC,” commented Rodney Varner, Chairman, President, and CEO of Genprex.

As the leading cause of cancer-related deaths globally, accounting for 1.8 million deaths in 2020 or about 18% of total cancer deaths (https://ibn.fm/TCEDH), lung cancer is an obvious example of a serious condition. (Lung cancer was also the second most common type of cancer in 2020, after female breast cancer, accounting for 2.2 million new cases.) With these numbers in mind, Genprex hopes to leverage its lead product candidate to help patients benefit from Tagrisso, Keytruda, or Tecentriq for a longer period of time and allow some patients to benefit who may not have benefited at all.

REQORSA consists of the TUSC2 tumor suppressor gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. “REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell,” explains Genprex’s website (https://ibn.fm/oWpT5).

According to Varner, data generated so far validates the company’s theory that using REQORSA in combination with these lung cancer therapies can extend the benefits of the drugs (https://ibn.fm/0QD5X). These findings are allowing the company to participate in the burgeoning lung cancer drugs market despite its relatively small size compared to AstraZeneca, Genentech, and Merck & Co, for example. Valued at $18.328 billion in 2018, the global lung cancer therapeutics market is expected to grow at a 13% CAGR reaching a value of $48.726 billion by 2026 (https://ibn.fm/R1u7R).

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Freight Technologies (aka Fr8Tech) has developed a technology solution that uses machine learning and artificial intelligence (“AI”) to help shipping and freighting companies optimize product transports and avoid costly errors
• Fr8Tech recently announced that one of its top clients, multinational insulation manufacturing company K-FLEX de México SA de CV, renewed its contract for using Fr8Tech’s core tech solution, Fr8App
• K-FLEX cited Fr8App’s benefits to the company during the difficult COVID-19 pandemic period and beyond as K-FLEX expanded its operations and approaches $1 billion in annual revenues
• Fr8Tech is continuing to expand its technology frontiers with the establishment of a dedicated AI development department within the company’s infrastructure

Supply chain optimization innovator Freight Technologies (NASDAQ: FRGT), aka Fr8Tech, helped shipping companies to keep commercial freight transportation rolling through the worst of the COVID pandemic, and the company’s dedication to its clients has resulted in a contract renewal with multinational insulation manufacturing company K-FLEX, according to a June 22 announcement.

“Fr8App delivered cross-border capacity during a difficult time for us as we worked first through the COVID-19 pandemic and then through our plant expansion challenges in Mexico and many times under conditions that others in the logistics industry were not willing to accept,” K-FLEX de México SA de CV President Maged Anis stated in the news release (https://ibn.fm/evIS0). “With our newly completed plant expansion, we will have over 100 trucks per week crossing from Mexico to the United States, and Fr8App’s solutions will play a huge role in managing our logistics seamlessly across the U.S.-Mexico border.”

Fr8Tech has assembled a family of brands surrounding its Fr8App flagship technology, which is an AI and machine learning technology that serves as a B2B freight matching platform. By simplifying the complicated process of securing international over-the-road (“OTR”) shipping, Fr8App makes it possible for freighting businesses to avoid costly errors and expand their operations.

Building on its automated strengths, Fr8Tech recently announced that it had appointed Dr. Umberto León-Domínguez to oversee the creation of a dedicated AI development department under the company’s banner to continue expanding the solutions the company can offer freighters.

“The vision of a future where AI fundamentally transforms goods transportation is exhilarating. In particular, the emergence of autonomous trucks and unmanned aerial vehicles holds the promise of increasing delivery efficiency and significantly reducing labor costs,” León-Domínguez stated (https://ibn.fm/AyHRO).

Fr8Tech’s area of operations includes shipping throughout the United States-Mexico-Canada Agreement trade area known as the USMCA (formerly NAFTA). León-Domínguez will be based in the company’s operations center in Monterrey, Mexico.

Fr8App allows users to network with each other to post their loads and the destination within the USMCA, along with the amount and desired price, and then provides matching options based on available cargo space in less-than-full truckloads already scheduled. It also provides tracking functionality for the shipment.

Fr8Tech CEO Javier Selgas noted that K-FLEX “is well on its way to surpassing $1 billion in annual revenue” and is one of Fr8Tech’s top clients, so the renewal is a cause for celebration. “We believe this is just the beginning of many great things to come,” he stated.

For more information, visit the company’s website at www.Fr8Technologies.com, and their its matching platform information site at www.Fr8.app. 

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

ZJ Events is proud to announce the third leg of its four-part Alternative Products Expo – the Dallas Chapter – that will be held at the Kay Bailey Hutchison Convention Center Dallas. The expo, which promises to be the ultimate event for anyone in the counterculture industry, will serve as a melting pot for everything counterculture, with featured products including CBD, mushrooms, nicotine replacement, dietary supplements, and nootropics, among others.

The event will be held from July 13-15, bringing together hundreds of leading brands such as 3Chi, Mellow Fellow, and Cali Kulture. The event will also offer a platform where attendees can connect with top manufacturers, explore the latest trends and innovations, and even take advantage of exclusive show discounts in a fun and exciting atmosphere.

The Dallas Alternative Products expo will allow business owners to stock their businesses with consumer must-haves. Show-exclusive pricing will make this possible, extending to individual consumers or attendees. The event will also be an excellent avenue for getting updated on trends, new products, and hot sellers in the market while also serving as a one-stop shop for counterculture retail professionals.

The Dallas leg of the 2023 Alternative Products Expo stays true to ZJ Events’ mission to facilitate B2B and B2C networking by vertically incorporating the event’s target industry and its complementary services into an unrivaled trade show experience. By gathering the industry’s best under the same roof while providing attendees with a fun, thrilling experience that promotes business networking, the company is promoting counterculture industry expansion while helping to define a budding sector with incredible potential for growth.

To learn more, please visit https://ibn.fm/yy1Oc.

For ticketing info, please visit https://ibn.fm/BAzDL.

• FEXD acknowledges the recent big data boom that has introduced tech-driven solutions in the current financial services space
• AI, through its many forms, has proven to be a viable technology to integrate into the financial service space, a development that FEXD recognizes and welcomes
• Through its focus on the benefits of AI, the company is pushing its adoption while also pushing the conversation forward
• It is doing so while also exploring ways it can further develop this technology to address unmet mobile money needs, both in developing and industrialized countries and markets

Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is pushing the conversation around the use of artificial intelligence (“AI”) to power financial solutions, and for a good reason. As a company that understands the financial space, FEXD knows the potential that AI has to transform the space, and the value it brings in transforming an industry that has, for a long time, arguably lacked innovation.

FEXD acknowledges the recent big data boom that has disrupted banking. With big data, financial services organizations can offer more personalized services with a 360-degree view of the customer’s interaction with their brand. In addition, the morphing regulatory requirements have introduced tech-driven solutions geared toward addressing emerging challenges in the current financial systems. Competition has also forced many players to be innovative, challenging them to adopt tech to have the edge over their peers (https://ibn.fm/CBfuP).

AI, through its many forms, has proven to be a viable aspect of integrating into the financial service space, a development that FEXD recognizes and welcomes. With a growing range of applications, from simple chatbots to credit risk management tools, AI is finding its way to the core of financial solutions, and all stakeholders welcome it. So far, JPMorgan Chase, critical among other players in its space, has reported leveraging AI for fraud detection for its account holders. As a showcase of what AI is capable of, the bank has been able to implement a proprietary algorithm that detects fraud patterns, earning it high scores in both security and reliability (https://ibn.fm/35z4k).

This, along with other additional benefits, such as speeding up services, allowing financial institutions to make more informed risks, and creating avenues for better customer relationship management, point to the potential of AI in the financial space. By focusing on such, FEXD is pushing the AI conversation forward while exploring ways to develop this technology further to address unmet mobile money needs in developing and industrialized countries and markets. Through mergers and acquisitions with fintech pioneers, the company is establishing a global fintech ecosystem while advancing the development of proprietary technologies and applications designed to keep the company ahead of its peers. AI is a fundamental aspect of its innovations, and with this focus, the company is shedding light on its potential and value in the financial services space.

For more information, visit the company’s website at www.FintechEcoSys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

• Ford Motor Co. recently announced a $9.2 billion government loan for constructing three battery factories in the U.S.
• This is seen as a move that seeks to stir the growth of domestic EV battery manufacturing in the country in response to the growing demand for green technologies
• Ucore recognizes this demand, and through its transformative commercial-ready technology, RapidSX(TM), it looks to satisfy it and take control of the North American REE supply chain
• The company is well aware of the developments within its industry and is well positioned to take advantage of them and become the undisputed leader in the North American market

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company with a vision and plan to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry, is expected to benefit significantly given its focus on taking control of the North American rare earth elements (“REE”) supply chain. This follows the recent $9.2 billion government loan to Ford Motor Co. for constructing three battery factories, seeking to stir the growth of domestic EV battery manufacturing in the country (https://ibn.fm/Rbi73).

Considered the biggest government backing for a U.S. automaker since the bailouts back in the 2009 financial crisis, this loan is seen by many, including car manufacturers, as the government’s move to incentivize local companies to devise and explore ways to not only come up with technology to harness the natural resources already present in North America but also grow industries around it. The objective is to, ultimately, do away with the current supply chain, which is highly dependent on China.

Ucore, through its transformative commercial-ready technology, RapidSX(TM), looks to satisfy this need to become a leading advanced technology company with best-in-class metal separation products and services to the mining and mineral extraction industry. Its unique value proposition has seen the company differentiate itself from its peers, and its confidence in its technology has seen its aggressive expansion and investment into the development of a heavy and light rare-earth processing facility in Louisiana.

“We are more confident than ever that Ucore’s planned rare earth separation facility in Louisiana will be a critical component of a North American rare earth supply chain,” noted Pat Ryan, Ucore’s Chairman, and CEO.

RapidSX(TM) combines the time-proven chemistry of conventional solvent extraction (“SX”) with a new column-based platform, significantly reducing time to completion and plant footprint. This technology also offers the potential to lower capital and operating costs, resulting in a more efficient process than the industry standard. Its scalable and modular nature also makes it ideal for the country’s current approach of ramping up its REE production capacity. In addition, its feedstock adaptability makes it readily configurable for separating any light or heavy REE (“LREE, HREE”) using the same equipment.

Ford Motor Co. has already committed to a $3.5 billion investment in an electric-vehicle battery plant in Michigan. Though controversial, the company has noted that it will operate with technology and support from China’s Contemporary Amerex Technology Co. Ltd., describing it as a “licensing” that will allow its engineers to “gain that knowledge so we can eventually do it ourselves” (https://ibn.fm/tDyxV).

With such steps and massive investments being made, it is only a matter of time before North America catches up, cuts into China’s advantage in EV batteries, and takes control of the global REE supply chain. Ucore is well aware of these developments and is ready to take advantage of them.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services
• BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May
• BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities
• The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining BiondVax’s core focus of NanoAb therapies for significant indications like COVID-19, psoriasis, asthma, and more

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently showcased the expansion of its service to begin offering services as a contract development and manufacturing organization (“CDMO”). These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (“GMP”) biologics manufacturing facility in Jerusalem.

In May, BiondVax showcased its boutique end-to-end CDMO services and expertise at a leading conference for international Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. The company’s CDMO services are designed to meet the needs of pharmaceutical and biotechnology companies of all sizes, with a commitment to providing customers with the highest levels of quality and service.

BiondVax’s CDMO offers a comprehensive range of services and assets, including:

• cGMP manufacturing of biologics at FDA and EMA standards
• State-of-the-art laboratories for manufacturing process development and scale-up
• Deep pharma experience and leadership to help accelerate products forward

The company’s cGMP manufacturing suites include clean rooms for upstream fermentation, downstream purification, labeling and visual inspection. It has previously passed the required audits for Phase 3 clinical trial production and more – which can be found in BiondVax’s CDMO literature. (https://ibn.fm/25F09).

“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a year-end letter to stakeholders. In a March interview, he also said his team has proven experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — with everything working like an oiled machine (https://ibn.fm/b9ZHc). “Also, the capacity and the capabilities are there.”

BiondVax’s NanoAbs, also known as VHH-antibodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies. These advantages include stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. The company is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

BiondVax’s development of NanoAb therapies addresses diseases that are currently underserved by current treatments, with large growing markets. In addition to COVID-19, the growing market outlook for asthma and psoriasis supports BiondVax’s focus on creating efficient therapies for patients in these indications.

Recent company statements on its quarterly financial results noted that it has already begun R&D activities for an innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis.

Adding the CDMO services will keep the team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb focus – targeting COVID-19, psoriasis, asthma, and more.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy
• Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension
• The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection crucial in commercial markets
• To date, Lexaria has a robust intellectual property portfolio with 34 patents granted and many more pending worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the publishing of its groundbreaking research utilizing DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) in eight peer-reviewed articles in six different publications. Since 2016, the company’s patented DehydraTECH(TM) technology has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors, and more.

These publications build on Lexaria’s growing body of peer-reviewed literature developed on the company’s leading research into the effects of DehydraTECH-CBD on human health, including indications such as hypertension. The most recent paper is entitled, “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study,” which was published in June 2023 in the International Journal of Molecular Sciences (https://ibn.fm/DOLxN).

“We’re proud of the impressive amount of research that our company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://ibn.fm/5zp9P). “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”

Additional publications include the following, which are also available at PubMed:

• September 2019, “Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects,” published in the journal Advances in Therapy (https://ibn.fm/36rvQ)
• June 2022, “Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for Randomized, Placebo-Controlled, and Crossover Study,” published in the Journal of Personalized Medicine (https://ibn.fm/B9vW8)
• April 2023, “Trial of a Novel Oral Cannabidiol Formulation in Patients with Hypertension,” published in Pharmaceuticals (https://ibn.fm/HDhBE)
• April 2023, “Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension,” published in Cannabis and Cannabinoid Research (https://ibn.fm/2kmuK)
• April 2023, “CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system,” published in Biomedicine & Pharmacotherapy (https://ibn.fm/S2k56)
• June 2023, “The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension,” published in Advances in Therapy (https://ibn.fm/KVM9x)
• June 2023, “Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension,” published in Biomedicine & Pharmacotherapy (https://ibn.fm/tsXZe)

The global cardiovascular drug market was worth $146.5 billion in 2022 and is expected to reach $173.5 billion in 2026 (https://ibn.fm/Xmz4z). By region, North America is the biggest market in the world, making US patent protection necessary in the pursuit of commercial markets. The fields of diabetes and heart disease are broad but emerging markets making them two primary areas of interest for Lexaria – where DehydraTECH-CBD has already generated positive study data. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 34 patents granted and many more pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• FRGT just announced its new integration with Samsara, the pioneer of Connected Operations(TM) Cloud
• The move is seen as a “gamechanger,” with Fr8App customers now able to view and leverage insights from Samsara’s vehicle telematics solution
• Fr8App’s management is confident that by connecting with industry leaders like Samsara, the company will continue to pave the way for streamlined logistics processes and improved visibility for customers
• In addition, the move solidifies Fr8App’s position as the most connected and integrable platform for cross-border shipping in North America

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, just announced its new integration with Samsara, a pioneer of the Connected Operations(TM) Cloud. The move has been termed as a significant development for platform users from both sides, with privileges ranging from real-time access to location data which, in turn, allows customers to make informed decisions and attend to unexpected changes or delays while their products are shipping (https://ibn.fm/GA53O).

The move has been lauded by Samsara users, terming it a “game-changer.”

“As a carrier currently using Samsara for track and trace, I can confidently say that the integration with Fr8App has been a game changer for our business,” noted Juan Pablo Villanueva, Operations Director of Transportes Americanos, a transportation company with operations in the U.S. Canada, and Mexico.

“Not only do we continue to benefit from Samsara’s reliable and efficient tracking capabilities, but now we can seamlessly share that information with Fr8App’s digital platform, offering Fr8App’s platform users real-time location updates without any additional steps or downloads required,” he added.

Samsara’s Connected Operations Cloud has helped differentiate the company in its segment by making it easy for organizations to access, analyze and act upon real-time data from tracks, trailers, warehouses, and equipment. In turn, users have enjoyed improved safety, efficiency, and sustainability, allowing for better and even more profitable operations. With the integration, Fr8App customers can now view and leverage insights from Samsara’s vehicle telematics solution, which is integral to optimizing logistics operations and ensuring timely delivery. Some of the vehicle telematics include but are not limited to, GPS tracking, streamlined compliance management, and advanced diagnostic reporting.

“We are very excited to integrate with Samsara to offer our customers an even better and more seamless experience,” noted Javier Selgas, Fr8Tech’s CEO.

“By connecting with industry leaders like Samsara, Fr8App continues to pave the way for streamlined logistics processes and improved visibility for customers,” he added.

This integration proves Fr8App’s distinctive approach to incorporating critical players in the logistics space. It further solidifies the company’s position as the most connected and integrable platform for cross-border shipping in North America while showcasing its commitment to delivering the best possible service to customers.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com